Table 1 Literatures relevant to the association of aspirin use and survival of patients with lung cancer
Source | Year | Country | Cell type | Stage | Study design | Study base | Sample size (users/non users) | HR (95%CI) for OS |
|---|---|---|---|---|---|---|---|---|
Ratnasinghe et al. [15] | 2004 | USA | N/A | N/A | Prospective cohort | NHANES I&II | 410 (178/232) | 0.81 (0.62-1.07) |
Cook et al. [11] | 2005 | USA | N/A | N/A | Randomized, double-blind, placebo-controlled | WHS | 140 (58/82) | 0.70 (0.50-0.99) |
Fontaine et al. [16] | 2010 | UK | NSCLC | I-III | Prospective cohort | Hospital based | 1765 (412/1353) | 0.84 (N/A) |
Brasky et al. [17] | 2012 | USA | N/A | N/A | Prospective cohort | VITamin And Lifestyle | 434 (83/351) | 0.99 (0.74–1.33) |
Wang et al. [18] | 2015 | USA | NSCLC | III | Retrospective cohort | Hospital-based | 673 (141/532) | 0.97 (0.78–1.20) |
McMenamin et al. [19] | 2015 | UK | N/A | N/A | Retrospective cohort | Population-based | 13,388 (N/A) | 1.00 (0.95–1.05) |
Veitonmäki et al. [20] | 2016 | Finland | N/A | N/A | Retrospective cohort | FinRSPC | 47 (3/44) | 1.03(0.85–1.26) |
Maddison et al. [21] | 2017 | UK | SCLC | N/A | Prospective cohort | Hospital-based | 313 (71/242) | 0.987 (0.754-1.293) |
Kang et al. et al. [22] | 2020 | Korea | N/A | N/A | Retrospective cohort | Population-based | 5938 | 1.03 (0.97-1.10) |
Our work | 2020 | Taiwan | NSCLC | Inoperable | Retrospective cohort | Population-based (NHIRD) | 38,842 | 0.79 (0.75–0.83) |